作者

Matthew Royle, Ph.D.

合伙人

Read More

Evelyne Friedel

合伙人

Read More

Judith Krens

合伙人

Read More
作者

Matthew Royle, Ph.D.

合伙人

Read More

Evelyne Friedel

合伙人

Read More

Judith Krens

合伙人

Read More

2019年6月30日 | 58:58

Webinar: Recent legislative developments affecting biologics and biosimilars

Many of the top-selling drugs worldwide are biologics, and several companies are seeking to produce biosimilars to compete in these lucrative markets.

Recently, a flurry of proposed legislation has threatened to drastically alter the US regulation of and policies on wide ranging topics such as drug pricing, mandatory licensing, patent thickets, and the availability of post-grant proceedings.

Session 2 of our 2019 biosimilars webinars series focuses on key factors decision makers need to be aware of when considering currently pending legislation, including:

  • Key provisions of proposed legislation.
  • European perspectives and approaches to similar issues.
Call To Action Arrow Image

Latest insights in your inbox

Subscribe to newsletters on topics relevant to you.

Subscribe
Subscribe

Related Insights

centrifuge-machine
酒店与休闲

Dissecting the Regeneron v Kymab mouse case – what it says and its impact on patents

2020年7月27日
QUICK READ

作者

点击此处了解更多
woman-with-scientific-model
酒店与休闲

Everything biologic and biosimilar in-house counsel need to know about COVID-19

2020年4月29日

作者

点击此处了解更多

相关活动